Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

Anteo Diagnostics Limited

ABN

75 070 028 625

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

Unlisted Options

- 2 Number of *securities issued or to be issued (if known) or maximum number which may be issued
- Principal terms of the 3 +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

9,000,000 Unlisted Options

9,000,000 \$.12 cent unlisted options expiry date o8 November 2017

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	Yes
	 If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	
5	Issue price or consideration	Nil
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	To issue options as approved at the 2013 AGM
6a	Is the entity an +eligible entity	Yes
Ud .	that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h <i>in relation to the +securities the</i> <i>subject of this Appendix 3B</i> , and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	31 October 2013
6с	Number of ⁺ securities issued without security holder approval under rule 7.1	Nil

⁺ See chapter 19 for defined terms.

- 6d Number of +securities issued Nil with security holder approval under rule 7.1A
- 6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of securities issued under an exception in rule 7.2
- 6g If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.
- 6h If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 Dates of entering *securities into uncertificated holdings or despatch of certificates
- 8 Number and ⁺class of all ⁺securities quoted on ASX (*including* the securities in section 2 if applicable)

Number	+Class
770,351,591	Fully Paid Ordinary Shares

d Nil

N/A

Nil

N/A

N/A

o8 November 2013

+ See chapter 19 for defined terms.

9

	Number	+Class
Number and ⁺ class of all ⁺ securities not quoted on ASX (<i>including</i> the securities in	28,225,000	7.0 c options expiring 8/11/2014
section 2 if applicable)	9,000,000	12.0c options expiring 08/11/2017
	9,600,000	12.0c options expiring 24/10/2015
	2,500,000	12.0c options expiring 24/10/2015
	500,000	12.0c options expiring 31/10/2015
	3,656,206	15.6c options expiring 18/12/2013
	71,643	15.6c options expiring 24/5/2014
	71,987	15.6c options expiring $1/10/2014$
	3,087,902	15.6c options expiring 20/12/2014
	105,865	15.6c options expiring $20/1/2015$
	58,166	15.6c options expiring $20/2/2015$

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

of a N/A the

Part 2 - Bonus issue or pro rata issue

⁺ See chapter 19 for defined terms.

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the ⁺ securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be	N/A
	aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	N/A
		[
18	Names of countries in which the entity has ⁺ security holders who will not be sent new issue	N/A
	documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
	•	

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of ⁺ security holders	N/A
25	If the issue is contingent on ⁺ security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do ⁺ security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do ⁺ security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

⁺ See chapter 19 for defined terms.

32 How do ⁺security holders dispose of their entitlements (except by sale through a broker)?

N/A			

33 ⁺Despatch date

N	'A
1 1/	11

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of securities (*tick one*)
- (a)

(b)

Securities described in Part 1

All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to a	indicate	you	are	providing	the	information	or
docume	nts						

35	5

- If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
- 36 If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over

37

A copy of any trust deed for the additional +securities

⁺ See chapter 19 for defined terms.

Number of securities for which ⁺quotation is sought

- Class of +securities for which quotation is sought
- Do the ⁺securities rank equally in all respects from the date of allotment with an existing ⁺class of quoted +securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution interest or
- Reason for request for quotation

Example: In the case of restricted securities, end

(if issued upon conversion of another security, clearly identify that other security)

+class and of all quoted on ASX (including the securities in clause

⁺ See chapter 19 for defined terms.

Quotation agreement

- ¹ ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the ⁺securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

(Company secretary)

Date:07/11/2013

Print name:Shane Hartwig.....

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

== == == == ==

Calculation of placement capacity under rule 7.1 and rule 7.1A for *eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Add the following:	nil	
 Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2 		
 Number of fully paid ordinary securities issued in that 12 month period with shareholder approval 		
 Number of partly paid ordinary securities that became fully paid in that 12 month period 		
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
<i>Subtract</i> the number of fully paid ordinary securities cancelled during that 12 month period	nil	
"A"	770,351,591	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"				
"B"	0.15			
	[Note: this value cannot be changed]			
<i>Multiply</i> "A" by 0.15	115,552,739			

Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used

"A" x 0.15 Note: number must be same as shown in	115,552,739
Step 4: Subtract "C" from ["A" x "I placement capacity under rule 7.1	3"] to calculate remaining
"C"	nil
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
Under rule 7.1AWith security holder approval under rule 7.1 or rule 7.4	
• Under an exception in rule 7.2	
Insert number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	nil

nil

115,552,739

capacity under rule 7.1]

[Note: this is the remaining placement

Note: number must be same as shown in

Subtract "C"

Total ["A" x 0.15] - "C"

Step 3

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	770,351,591	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<i>Multiply</i> "A" by 0.10	77,035,159	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	nil	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		
"E"	nil	

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	77,035,159
Note: number must be same as shown in Step 2	
Subtract "E"	nil
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	77,035,159

⁺ See chapter 19 for defined terms.